News archive
Showing 692 results
July 2019
-
Media Release
Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home
-
Media Release
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
- FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from… -
Media Release
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
-
Media Release
Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
- BRAF mutation status is an important factor when choosing a first-line therapy for patients with stage III and stage IV melanoma- The Know Now Testing Program covers cost of this genetic mutation… -
Media Release
Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
June 2019
-
Media Release
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
- Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine-… -
Media Release
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
-
Media Release
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
- Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (… -
Media Release
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
May 2019
-
Media Release
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
- One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA- Annualized cost of Zolgensma is USD 425,000… -
Media Release
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
- SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1,2]-… -
Media Release
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families